Biological evaluation of an ornithine-modified 99mTc-labeled RGD peptide as an angiogenesis imaging agent

Due to its relatively high tumor uptake, renal elimination and negligible abdominal localization, the new 99mTc-RGD peptide is considered promising in the field of imaging ανβ3-positive tumors. However, the preparation of multifunctional SPECT/MRI contrast agents (RGD-conjugated nanoparticles) for dual modality imaging of integrin expressing tumors should be further investigated.